In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sandoz International GmbH

Latest From Sandoz International GmbH

Biocon Boosts Biosimilars In Australia With Sandoz Partnership

Biocon Biologics is seeking to bolster its biosimilars business in Australia, recently integrated after being acquired from former owner Viatris, through a deal that will see Sandoz market its Ogivri and Abevmy versions of trastuzumab and bevacizumab.

Deals Biosimilars

Who’s Hired? Sandoz Freshens Up Directors Board After Pivotal Year

Sandoz nominated a new director candidate ahead of its annual meeting and Lantheus welcomed a familiar face as the new CEO. Meanwhile, Mallinckrodt strengthened its board with four new directors and Hikma announced another appointment this year.

Executive Changes Leadership

How Firms Are Using ICH Q12 Guideline To Reduce US FDA Oversight Of Manufacturing Changes

Sandoz reduced established conditions by 19% in one BLA; others are having similar successes in focusing change control oversight more narrowly. But there have been some pitfalls.

Manufacturing Quality

Sandoz Rolls Out Natalizumab Biosimilar In Germany

Sandoz is rolling out its Tyruko natalizumab biosimilar rival to Biogen’s Tysabri in Germany, heralding the product as the “first and only biosimilar for multiple sclerosis.”

Launches Biosimilars
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs